Form 4: Integra LifeSciences CLO Granted 89,606 RSUs

Integra LifeSciences Holdings Corp.'s EVP, Chief Legal Officer, Michael Hutchinson, was granted 89,606 restricted stock units.

Summary

• Michael Damon Hutchinson, Executive Vice President, Chief Legal Officer & Secretary of Integra LifeSciences Holdings Corp. (IART), was granted 89,606 Restricted Stock Units (RSUs).
• The grant date for these RSUs was February 2, 2026.
• The RSUs will vest 100% on the second anniversary of the grant date, which is February 2, 2028.
• Each RSU represents a right to receive one share of Integra LifeSciences Holdings Corp. common stock upon vesting, with an acquisition price of $0.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine executive compensation event, aligning management incentives with long-term company performance, which is generally a positive for corporate governance and stability.

Positives

• The grant of 89,606 Restricted Stock Units to a key executive, Michael Hutchinson, aligns his interests with long-term shareholder value.
• The two-year vesting schedule encourages executive retention and sustained performance over the specified period.

Risks

• The ultimate value realized from the Restricted Stock Units is directly tied to the future market performance of Integra LifeSciences Holdings Corp.'s common stock, exposing the executive to market fluctuations.
• If the company's stock price declines significantly before the vesting date, the actual value received by the executive will be lower than the value at the grant date.

Future Outlook

The grant of Restricted Stock Units with a two-year vesting period indicates an expectation of continued executive tenure and performance contributing to future company value.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units, are a common component of executive compensation packages across the medical technology and life sciences industries. This practice aims to align executive incentives with long-term shareholder interests and promote retention.

Comparison to Industry Standards

• Equity compensation through Restricted Stock Units is a standard practice in the life sciences sector, comparable to companies like Medtronic (MDT) or Stryker (SYK), which frequently use RSUs to incentivize and retain key executives.
• The two-year vesting schedule is within typical industry ranges for executive equity grants, which often vary from one to five years depending on the specific role and company policy.

Stakeholder Impact

• Shareholders: The grant aligns executive interests with shareholder value creation over the vesting period.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• The 89,606 Restricted Stock Units are scheduled to vest on February 2, 2028.

Key Dates

Recommendation

This Form 4 reports a routine executive equity grant, which is a standard compensation practice. It does not provide new information that would fundamentally alter the investment thesis for Integra LifeSciences Holdings Corp., thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Integra LifeSciences, IART, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Michael Hutchinson, Equity Grant